Regardless of kidney function, raloxifene therapy increased spine bone mineral density and cut the risk of spinal fractures, but had no effect on other types of fractures compared with to placebo.
No significant differences in adverse events were noted between raloxifene and placebo in any of the kidney function groups, the findings indicate.
The results, the authors conclude, support the use of raloxifene as a safe and effective means to increase bone mineral density and prevent vertebral fractures in postmenopausal women with osteoporosis and compromised kidney function.
SOURCE: Journal of the American Society of Nephrology, April 9, 2008.
